Infliximab as a potential treatment for COVID-19
Author:
Affiliation:
1. Department of Medicine, Weill Cornell Medicine, New York, NY, USA
Publisher
Informa UK Limited
Subject
Virology,Infectious Diseases,Microbiology (medical),Microbiology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14787210.2023.2151438
Reference65 articles.
1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022 Sept 1 cited 2022 Sept 1]
2. Available from 2022 Sept 1: https://covid19.who.int/.
3. Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—a cautionary case series
4. COVID-19 and immunomodulation in IBD
5. Immunopathogenesis of COVID-19 and early immunomodulators
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluation of infliximab-induced genotoxicity and possible action on BCL-2 and P53 genes;Journal of Toxicology and Environmental Health, Part A;2024-06-26
2. Anti-cytokine strategies targeting CAR-T cell therapy-induced cytokine release syndrome;Third International Conference on Biological Engineering and Medical Science (ICBioMed2023);2024-01-08
3. An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic;International Journal of Molecular Sciences;2023-12-26
4. Signaling pathways in macrophages: molecular mechanisms and therapeutic targets;MedComm;2023-09-11
5. COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs;DARU Journal of Pharmaceutical Sciences;2023-08-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3